Deals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease
Abogen BiosciencesmRNA

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Abogen Biosciences Co., Ltd. ("Abogen"), a clinical‑stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis AG (NYSE: NVS) to advance…

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital
Betta PharmaceuticalsBiotech

Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital

Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures
BiotechFinance

Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures

AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
AbbVieBMS

AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer

HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
CancerEli Lilly

HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales

Show More